

Neutrophil to Lymphocyte Ratio and Neurological Outcome in Ischemic Stroke at 4.5 to 24 Hours: A Post-hoc Analysis of TRACE-III Trial

Manjun Hao, M.D.^{1#}, Yujie Ma, M.D.^{1#}, Lihua Wang, M.D.^{2#}, Aoming Jin, Ph.D.³,
Zhe Kang Law, M.D., Ph.D.⁴, Bruce C.V. Campbell, M.B.B.S., Ph.D.⁵, Lee H.
Schwamm, M.D.⁶, Mark W. Parsons, M.B.B.S., Ph.D.⁷, Marc Fisher, M.D.⁸, Yuming
Xu, M.D., Ph.D.⁹, Anding Xu, M.D., Ph.D.¹⁰, Zhixin Cao, M.D.¹, Liyuan Wang,
M.D.¹, Shuangzhe Wu, M.D.¹, Yongjun Wang, M.D.^{1,3,11,12*}, Yunyun Xiong, M.D.,
Ph.D.^{1,3*}.

1. Department of Neurology, Beijing Tiantan Hospital, Capital Medical University,
Beijing, China

2. Department of Neurology, Second Affiliated Hospital of Harbin Medical University,
Harbin, China

3. China National Clinical Research Center for Neurological Diseases, Beijing, China

4. Department of Medicine, Faculty of Medicine, National University of Malaysia,
Malaysia

5. The Department of Medicine and Neurology, Royal Melbourne Hospital, The
University of Melbourne, Parkville, Australia

6. Yale New Haven Health System, Yale School of Medicine, New Haven, CT, USA

7. The Department of Neurology, University of New South Wales South Western Sydney Clinical School, Liverpool, Australia
8. The Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA
9. The Department of Neurology, First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China
10. The First Affiliated Hospital of Jinan University, Guangzhou, China
11. The Advanced Innovation Center for Human Brain Protection, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
12. The Research Unit of Artificial Intelligence in Cerebrovascular Disease, Chinese Academy of Medical Sciences, Beijing, China

#Manjun Hao, Yujie Ma and Lihua Wang contributed equally.

Correspondence to:

Yunyun Xiong, MD, PhD, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, No. 119, S. 4th Ring W. Rd., Fengtai District, Beijing 100070, China (xiongyunyun@bjtth.org);

Yongjun Wang, MD, China National Clinical Research Center for Neurological

Diseases, Beijing Tiantan Hospital, Capital Medical University, No. 119, S. 4th Ring

W. Rd., Fengtai District, Beijing 100070, China (yongjunwang@ncrcnd.org.cn)

Table S1. Neurological and Non-Neurological hospital mortality According to baseline NLR Level and Treatment

Characteristics	Baseline NLR ≤ 3.0 (N=127)		Baseline NLR > 3.0 (N=386)	
	Tenecteplase (N=62)	Standard Medical Treatment (N=65)	Tenecteplase (N=202)	Standard Medical Treatment (N=184)
Hospital mortality, no. (%)	1 (1.6%)	1 (1.5%)	3 (1.5%)	5 (2.7%)
Neurological hospital mortality	1	0	3	2
Non-neurological hospital mortality	0	1	0	3

NLR, Neutrophil to Lymphocyte Ratio.